ALNYLAM PHARMACEUTICALS, INC. Depreciation, Amortization and Accretion, Net
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Depreciation, Amortization and Accretion, Net of $27.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationAmortizationAndAccretionNet · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for the quarter ending 2025-12-31 was $13.51M, a 4.67% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for the quarter ending 2025-09-30 was $13.80M, a 1.28% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for the quarter ending 2025-06-30 was $13.94M, a 7.06% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for the quarter ending 2025-03-31 was $14.40M, a 6.57% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for fiscal 2025 was $55.66M, a 1.79% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for fiscal 2024 was $56.67M, a 4.84% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for fiscal 2023 was $54.05M, a 21.56% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. depreciation, amortization and accretion, net for fiscal 2022 was $44.47M, a 6.52% decline from fiscal 2021.
| Period end | Depreciation, Amortization and Accretion, Net 3 month | Depreciation, Amortization and Accretion, Net 3 month as first filed | Depreciation, Amortization and Accretion, Net 6 month | Depreciation, Amortization and Accretion, Net 6 month as first filed | Depreciation, Amortization and Accretion, Net 9 month | Depreciation, Amortization and Accretion, Net 9 month as first filed | Depreciation, Amortization and Accretion, Net 12 month | Depreciation, Amortization and Accretion, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $27.45M 10-Q · filed 2026-07-30 | |||||||
| 2025-12-31 | $13.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $27.31M derived: sum of 2 quarters · filed 2026-02-12 | $41.25M derived: sum of 3 quarters · filed 2026-07-30 | $55.66M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $13.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $27.75M derived: sum of 2 quarters · filed 2026-07-30 | $42.15M 10-Q · filed 2025-10-30 | $56.32M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $13.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $28.35M 10-Q · filed 2026-07-30 | $42.52M derived: sum of 3 quarters · filed 2026-07-30 | $56.50M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $14.40M 10-Q · filed 2025-05-01 | $28.57M derived: sum of 2 quarters · filed 2026-02-12 | $42.55M derived: sum of 3 quarters · filed 2026-02-12 | $57.56M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-12-31 | $14.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $28.15M derived: sum of 2 quarters · filed 2026-02-12 | $43.15M derived: sum of 3 quarters · filed 2026-02-12 | $56.67M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $13.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $28.98M derived: sum of 2 quarters · filed 2025-10-30 | $42.50M 10-Q · filed 2025-10-30 | $55.98M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $28.52M 10-Q · filed 2025-07-31 | $42.00M derived: sum of 3 quarters · filed 2026-02-12 | $55.33M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $13.52M 10-Q · filed 2025-05-01 | $27.00M derived: sum of 2 quarters · filed 2026-02-12 | $40.33M derived: sum of 3 quarters · filed 2026-02-12 | $53.51M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $13.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $26.81M derived: sum of 2 quarters · filed 2026-02-12 | $39.99M derived: sum of 3 quarters · filed 2026-02-12 | $54.05M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $13.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $26.51M derived: sum of 2 quarters · filed 2024-10-31 | $40.57M 10-Q · filed 2024-10-31 | $54.88M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $13.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $27.24M 10-Q · filed 2024-08-01 | $41.55M derived: sum of 3 quarters · filed 2025-02-13 | $52.16M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $14.06M 10-Q · filed 2024-05-02 | $28.38M derived: sum of 2 quarters · filed 2025-02-13 | $38.98M derived: sum of 3 quarters · filed 2025-02-13 | $49.07M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $24.91M derived: sum of 2 quarters · filed 2025-02-13 | $35.01M derived: sum of 3 quarters · filed 2025-02-13 | $44.47M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $10.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $20.70M derived: sum of 2 quarters · filed 2023-11-02 | $30.16M 10-Q · filed 2023-11-02 | $41.53M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $19.56M 10-Q · filed 2023-08-03 | $30.93M derived: sum of 3 quarters · filed 2024-02-15 | $42.72M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $9.46M 10-Q · filed 2023-05-04 | $20.84M derived: sum of 2 quarters · filed 2024-02-15 | $32.62M derived: sum of 3 quarters · filed 2024-02-15 | $44.43M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $11.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $23.16M derived: sum of 2 quarters · filed 2024-02-15 | $34.97M derived: sum of 3 quarters · filed 2024-02-15 | $47.57M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $11.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $23.59M derived: sum of 2 quarters · filed 2022-10-27 | $36.19M 10-Q · filed 2022-10-27 | $46.58M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-06-30 | $11.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $24.41M 10-Q · filed 2022-07-28 | $34.79M derived: sum of 3 quarters · filed 2023-02-23 | $43.37M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2021-03-31 | $12.60M 10-Q · filed 2022-04-28 | $22.99M derived: sum of 2 quarters · filed 2023-02-23 | $31.56M derived: sum of 3 quarters · filed 2023-02-23 | $39.76M derived: sum of 4 quarters · filed 2023-02-23 | ||||
| 2020-12-31 | $10.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $18.96M derived: sum of 2 quarters · filed 2023-02-23 | $27.16M derived: sum of 3 quarters · filed 2023-02-23 | $34.77M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $8.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $16.77M derived: sum of 2 quarters · filed 2021-10-28 | $24.39M 10-Q · filed 2021-10-28 | $29.83M derived: sum of 4 quarters · filed 2022-02-10 | ||||
| 2020-06-30 | $8.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $15.81M 10-Q · filed 2021-08-03 | $21.25M derived: sum of 3 quarters · filed 2022-02-10 | $25.29M derived: sum of 4 quarters · filed 2022-02-10 | ||||
| 2020-03-31 | $7.61M 10-Q · filed 2021-04-29 | $13.05M derived: sum of 2 quarters · filed 2022-02-10 | $17.09M derived: sum of 3 quarters · filed 2022-02-10 | $20.95M derived: sum of 4 quarters · filed 2022-02-10 | ||||
| 2019-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $9.48M derived: sum of 2 quarters · filed 2022-02-10 | $13.34M derived: sum of 3 quarters · filed 2022-02-10 | $17.18M 10-K · filed 2022-02-10 | ||||
| 2019-09-30 | $4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $7.89M derived: sum of 2 quarters · filed 2020-11-05 | $11.73M 10-Q · filed 2020-11-05 | $21.16M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $3.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $7.69M 10-Q · filed 2020-08-06 | $21.95M 10-Q · filed 2019-08-06 | $17.12M derived: sum of 3 quarters · filed 2021-02-11 | $17.52M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2019-03-31 | $3.84M 10-Q · filed 2020-05-06 | $12.21M 10-Q · filed 2019-05-02 | $13.26M derived: sum of 2 quarters · filed 2021-02-11 | $13.67M derived: sum of 3 quarters · filed 2021-02-11 | $15.91M derived: sum of 4 quarters · filed 2021-02-11 | |||
| 2018-12-31 | $9.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $9.83M derived: sum of 2 quarters · filed 2021-02-11 | $12.07M derived: sum of 3 quarters · filed 2021-02-11 | $15.25M 10-K · filed 2021-02-11 | $6.43M 10-K · filed 2019-02-14 | |||
| 2018-09-30 | $405.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $2.64M derived: sum of 2 quarters · filed 2019-10-31 | $5.82M 10-Q · filed 2019-10-31 | $8.66M 10-Q · filed 2018-11-07 | $8.07M derived: sum of 4 quarters · filed 2020-02-13 | |||
| 2018-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $5.42M 10-Q · filed 2019-08-06 | $7.66M derived: sum of 3 quarters · filed 2020-02-13 | $11.25M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $3.18M 10-Q · filed 2019-05-02 | $5.42M derived: sum of 2 quarters · filed 2020-02-13 | $9.01M derived: sum of 3 quarters · filed 2020-02-13 | |||||
| 2017-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $5.83M derived: sum of 2 quarters · filed 2020-02-13 | $11.90M 10-K · filed 2020-02-13 | $13.37M 10-K · filed 2019-02-14 | ||||
| 2017-09-30 | $3.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $9.65M 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | $6.07M 10-Q · filed 2018-08-02 | |||||||
| 2016-12-31 | $15.13M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |